Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride tablets are an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. ( 1 ) FDA label
memantine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| memantine | DRUG | - |
Inclusion Criteria: * glaucoma damage on examination of visual field and optic disc * good visual acuity (with glasses if needed)
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Memantine is being studied as a treatment for open-angle glaucoma, a chronic eye condition. It is an investigational small molecule in Phase 3 development for this indication. Both completed Phase 3 trials enrolled adults with chronic glaucoma, and the program has not been approved for this use.
Memantine targets NMDA receptor subunits, specifically GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, and GRIN2D. It acts as a negative allosteric modulator of these receptors. This target class distinguishes its proposed mechanism in glaucoma from its other clinical uses.
AbbVie Inc. (ticker ABBV) is the developer associated with memantine in this open-angle glaucoma program. The company is listed as the sponsor of the Phase 3 clinical development effort for this indication.
Memantine is in Phase 3 development for open-angle glaucoma. Two Phase 3 trials have been completed, and no active trials are currently listed. It remains an investigational therapy for this indication and is not approved for open-angle glaucoma.
Two completed Phase 3 trials studied memantine in chronic glaucoma: NCT00168350, which enrolled 1,179 participants, and NCT00141882, which enrolled 1,119 participants. Both were randomized, double-blind studies in adults aged 18 years and older with open-angle glaucoma, totaling 2,298 participants.